Brimonidine Eye Drops to Slow Myopia in Kids
Official title: Brimonidine Eye Drops in the Prevention of Myopia Progression
Run by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · NCT06996236 · Data updated 2026-11-12
A small study will test whether brimonidine eye drops can slow myopia progression in children ages 6–14.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 6 Years to 14 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal Academic / other |
| Locations | 1 site (Madrid, Madrid) |
| Status | Recruiting |
| Started | December 17, 2025 |
| Main results expected | July 2027 |
| Study ends | July 2027 |
| Registry record updated | November 9, 2026 |
| Trial ID | NCT06996236 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children aged 6–14 with myopia between -1.50 and -5.50 D, low astigmatism, acceptable visual acuity, and suitable contraception considerations for those of childbearing potential.
✕Probably not a fit
Patients with higher myopia, significant astigmatism, or contraindications may not experience benefit or could be excluded for safety reasons.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 2 trial tests 0.025% brimonidine eye drops given once daily for 1–2 years to see if it slows the growth of the eye and progression of myopia in children. The study uses a local eye-drop delivery to minimize systemic effects and focuses on a regimen similar to other myopia treatments. Participants will have specific refractive, visual, and safety criteria and will be monitored for changes in axial length and vision over time.
Why it matters
Potential benefit: If successful, the treatment could slow myopia progression with a convenient, low-dose eye drop.
How similar studies have gone: Prior eye-drop approaches in myopia have shown mixed results; this is an early-phase study exploring a similar topical strategy with brimonidine.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 6 to ≤ 14 years * Patients who, after having received information about the design, the purposes of the study, the possible risks that may arise from it and that at any time they may refuse to cooperate, give written consent to participate in the study (the patient older than 12 years and the legal representative) * Myopia ≥ -1. 50 Diopters of spherical equivalent, ranging from -1.50 to -5.50 D * Astigmatism with a cylinder power ≤ -1.50 Diopters * Anisometropia (refractive difference between both eyes) in spherical equivalent ≤ 1.25 Diopters * Visual acuity (CVA) \> 0.3 logMAR (0.5 on Snellen scale). * Intraocular pressure \< 20 mm Hg * In women of childbearing age negative urine pregnancy test performed within 7 days prior to the start of treatment * Women and men with partners of childbearing age must agree to use a highly effective method of contraception (such as surgical sterilization, double barrier method, oral contraceptives or hormonal contraceptive implants) and to continue using them until 6 months after the last dose of treatment. Exclusion Criteria: * Presence of any other ocular pathology (other than myopia) * History of allergy to the medications and excipients used in the study * History of previous therapy for myopia using eye drops, contact lenses or multifocal or bifocal glasses * Amblyopia (2 or more lines of difference in visual acuity between both eyes, on logMAR scale, with optical correction) * Any of the following situations present at the time: prolonged ocular hyperemia, prolonged ocular irritation, ocular infections - mucopurulent discharge in ocular tissues, ocular pain, vision changes/alterations other than myopia * Any clinical situation that at the investigator's discretion advises against participation.
Where it's running
-
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Spain Recruiting
Study contacts
- Principal investigator: Jaime Tejedor Fraile, MD — Hospital Universitario Ramon y Cajal
- Study coordinator: Jaime Tejedor Fraile, Md
- Email: tejedor.jaime@gmail.com
- Phone: 913368679 / 913369023
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating a device for screening vision problems in young children
This study is testing a new device to see if it can effectively find vision problems in children aged 3 to 8, whether they wear glasses or not.
-
Optimizing light exposure to prevent and control myopia in children
This study tests if changing classroom lighting to mimic sunlight or using a smartphone app to guide light exposure can help prevent and control myopia in primary school children.
-
Hyperopic reserve screening for kindergartners in Beijing
A population-wide screening tests whether senior kindergarten children in Beijing have enough hyperopic reserve to help prevent future myopia.
-
Do dual-focus multifocal contact lenses improve hand-eye coordination and sports vision compared with your usual lenses
This study tests whether wearing dual-focus multifocal contact lenses improves hand-eye coordination and sports vision in adults who play baseball or softball and normally wear contact lenses.
-
Two monthly silicone hydrogel multifocal toric contact lenses in wearers with astigmatism and myopia
This study tests whether two popular soft multifocal toric contact lenses perform differently in adults who need vision correction for astigmatism and myopia.
-
Seeing clearly in low light after Ray-Tracing guided LASIK
A trial tests how well WaveLight Plus LASIK works for people with myopia and astigmatism and whether patients are satisfied after the procedure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.